Despite being on the market for less than three years, GLP-1 medicines, Mounjaro and Zepbound, became key top-line drivers ...

Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline.

WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies ...

Mosaic Therapeutics a UK-based oncology company has announced it has in-licensed two clinical-stage oncology programmes from Astex Pharmaceuticals. The agreement transforms Mosaic from a ...

On Thursday, HC Wainwright downgraded LAVA Therapeutics to Neutral from Buy with a price target of $1.50, citing pipeline overhang despite substantial cash reserve.

Foghorn Therapeutics ( (FHTX)) has provided an announcement. Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter ...

The latest announcement is out from Aclaris Therapeutics ( (ACRS)). Aclaris Therapeutics has secured an exclusive license agreement with Biosion for global rights to promising biologics targeting ...

Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "Uremic Pruritus - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.The report provides comprehensive ...

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Denali Therapeutics (DNLI – Research Report), with a price target of $38.00. Mayank Mamtani’s Buy ...